Mr. Maoliang Li co-founded Chengdu New Radiomedicine Technology Co., Ltd. in 2016. He served as Chairman of the first Board of Directors of the company and Director of the Scientific Committee.

Mr. Li graduated from the University of Science and Technology of China (USTC). He is a Full-Professor and Ph.D. Advisor. He was the Deputy Director of the Reactor Operation Research Department of the Nuclear Power Institute of China, and the Director of Chengdu Isotope Application Research Institute. Mr. Li founded Chengdu Yunke Pharmaceutical company and served as the Chief Technology Officer. Mr. Li also served as the Vice Chairman of China Isotope and Radiation Industry Association, and Vice Chairman of Sichuan Nuclear Technology Application Association.

Mr. Li was one of the first Chinese visiting scholars to the United States after China’s reform and opening-up in the early 1980’s. He was recognized as a young and middle-aged expert with outstanding contributions to China National Nuclear Corporation and was one of the first recipients of State Council Special Allowance. Mr. Li was awarded three second-prize and five third-prize science and technology awards at the provincial and state level. Mr. Li has made outstanding contributions to the applied science and industry development of China nuclear technology.